Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Immuron, Ltd. (NASDAQ: IMRN).

Full DD Report for IMRN

You must become a subscriber to view this report.


Recent News from (NASDAQ: IMRN)

Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies
Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies
Source: OTC Markets
Date: April, 18 2017 00:00
Immuron Completes Phase II NASH Clinical Trial Recruitment
Immuron Completes Phase II NASH Clinical Trial Recruitment
Source: OTC Markets
Date: February, 20 2017 00:00
Immuron Initiates NASH MOA Studies with SanyalBio and with Duke University
Immuron Initiates NASH MOA Studies with SanyalBio and with Duke University
Source: OTC Markets
Date: January, 19 2017 00:00
European/US Analyst: Immuron Moving to Forefront in NASH
European/US Analyst: Immuron Moving to Forefront in NASH
Source: OTC Markets
Date: January, 18 2017 00:00
NASH Transactions by JNJ, BMS and Novartis, Highlight Continued Appetite for NASH Assets
NASH Transactions by JNJ, BMS and Novartis, Highlight Continued Appetite for NASH Assets
Source: OTC Markets
Date: January, 06 2017 00:00
Enjoy Your Holiday Travel and Protect Yourself from Food-Borne Illness with Travelan
Enjoy Your Holiday Travel and Protect Yourself from Food-Borne Illness with Travelan
Source: OTC Markets
Date: December, 22 2016 00:00
Immuron Files F-1 with the SEC
Immuron Files F-1 with the SEC
Source: OTC Markets
Date: December, 21 2016 00:00
IMROY - Books closed today, December 5, 2016
IMROY - Books closed today, December 5, 2016
Source: OTC Markets
Date: December, 05 2016 00:00
Immuron Receives $1.59M R&D Tax Concession Refund
Immuron Receives $1.59M R&D Tax Concession Refund
Source: OTC Markets
Date: November, 29 2016 00:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2035790.5181Cover
2018-08-175001,10045.4545Short
2018-08-151,6571,657100.0000Short
2018-08-1422536461.8132Short
2018-08-1015034743.2277Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IMRN.


About Immuron, Ltd. (NASDAQ: IMRN)

Logo for Immuron, Ltd. (NASDAQ: IMRN)

Immuron Ltd ASX: IMC OTCQB: IMROY is a microbiome company focused on developing and commercializing oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan for the prevention of Travelers diarrhea, whilst its lead product candidate IMM E is in Phase b clinical trials for NASH and ASH. These products together with the Company s other preclinical immunotherapy pipeline products targeting immune related diseases currently under development, will meet a large unmet need in the market.

 

Contact Information

 

 

Current Management

  • Dr.Jerry Kanellos / COO, Chief Scientific Officer
  • Peter Vaughan / CFO, Secretary
  • Phillip Allen Hains / CFO, Secretary
  • Dr. Dan Peres / Senior VP, SVP, Product Dev.
  • Agapitos Elefterios Peter Anastasiou / Executive Vice Chairman
  • Dr. Roger Aston / Director
  • Daniel Jude Pollock / Director
  • Stephen Anastasiou / NonExecutive Director

Current Share Structure

  • Market Cap: $22,561,309 - 05/16/2018
  • Issue and Outstanding: 105,641,417 - 03/02/2017

 


Recent Filings from (NASDAQ: IMRN)

144A Offering Announcement - Immuron Rights Issue Offer Booklet (May 2016)
Filing Type: 144A Offering Announcement - Immuron Rights Issue Offer Booklet (May 2016)Filing Source: OTC Markets
Filing Date: September, 18 2016
Research Report - US Analyst Reports on Immuron Products and R&D Pipeline
Filing Type: Research Report - US Analyst Reports on Immuron Products and R&D PipelineFiling Source: OTC Markets
Filing Date: September, 14 2016
Annual Report - Appendix 4E & Annual Financial Report for Year Ended 30 June 2016
Filing Type: Annual Report - Appendix 4E & Annual Financial Report for Year Ended 30 June 2016Filing Source: OTC Markets
Filing Date: September, 04 2016
Semi-Annual Report - Appendix 4D - Half Year Report - 31 Dec 2015
Filing Type: Semi-Annual Report - Appendix 4D - Half Year Report - 31 Dec 2015Filing Source: OTC Markets
Filing Date: May, 10 2016
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: September, 06 2015
Corporate Bylaws - Appendix 4G - Corporate Governance
Filing Type: Corporate Bylaws - Appendix 4G - Corporate GovernanceFiling Source: OTC Markets
Filing Date: September, 02 2015
Research Report - Red Chip Research Report
Filing Type: Research Report - Red Chip Research ReportFiling Source: OTC Markets
Filing Date: September, 02 2015
Officer/Director Disclosure - Peter Anastasiou Appointed Vice Chairman
Filing Type: Officer/Director Disclosure - Peter Anastasiou Appointed Vice ChairmanFiling Source: OTC Markets
Filing Date: September, 02 2015
Officer/Director Disclosure - Immuron Appoints New Chief Executive Officer
Filing Type: Officer/Director Disclosure - Immuron Appoints New Chief Executive OfficerFiling Source: OTC Markets
Filing Date: September, 02 2015
Officer/Director Disclosure - Immuron Appoints Chief Operating & Scientific Officer
Filing Type: Officer/Director Disclosure - Immuron Appoints Chief Operating & Scientific OfficerFiling Source: OTC Markets
Filing Date: September, 02 2015

 

 


Daily Technical Chart for (NASDAQ: IMRN)

Daily Technical Chart for (NASDAQ: IMRN)


Stay tuned for daily updates and more on (NASDAQ: IMRN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: IMRN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IMRN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of IMRN and does not buy, sell, or trade any shares of IMRN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/